INC Research, a global phase I to IV CRO, has launched its Catalyst program to strengthen collaborations with clinical research sites worldwide, in turn enhancing patient focus and optimizing study delivery to drive improved predictability of clinical trials and reduce development timelines for biopharmaceutical customers worldwide. 

INC’s Catalyst program includes two components—the Catalyst Site Network and the Catalyst Community—which focus on developing stronger collaborations with clinical research sites across the globe to drive continuous improvement and development of best practice in the delivery of clinical research. The program aligns closely with INC’s Trusted Process clinical development methodology, which focuses on reducing variability and increasing predictability to improve the conduct of clinical trials. INC’s Catalyst Site Network is a select group of high-performing sites strategically and therapeutically aligned both to its business and its customers, and the Catalyst Community is an online forum representing a broader range of sites to support ongoing collaboration and information exchange on the conduct of clinical trials, wider adoption of new methodologies and sharing of best practice. 

“Sites play an essential role in bringing new therapies to market for patients,” said Clare Grace, Ph.D., vice president, Site and Patient Access. “By involving them early on and making them a partner in the clinical development process, studies start more quickly and run more predictably, enabling INC to better deliver on the needs of our customers and ultimately accelerate the delivery of new therapies to patients. The launch of our Catalyst program underscores INC’s continued efforts and commitment to strengthening our connections with this critical stakeholder group to drive innovation in clinical research.”

INC Catalyst Sites will have the opportunity to participate in an increased volume of clinical trials, with a dedicated relationship manager supporting the site and facilitating optimal matching to protocols.  Participation in INC’s Catalyst Site network is by invitation only and initial focus of the program is on oncology and vaccine sites in the U.S. and Asia Pacific region, areas representing high-growth opportunity for the CRO industry and INC.

INC’s Catalyst Community will have access to many of the benefits enjoyed by the company’s Catalyst Sites via profile-targeted content. Sites will be able to manage their profile, observe their study performance and gain insight into pipeline opportunities while contributing to new methodologies in development. The Catalyst Community is open to all sites and is planned for launch in the second quarter of 2016. Unlike site network programs that are oriented around preferred partnerships, INC Research’s Catalyst program has been developed to deliver meaningful benefits to all stakeholders in the clinical research setting with the ultimate goal of maintaining maximum choice and opportunity for patients.